SCHEMBL514401

SCHEMBL514401

C1CN2CCCN(C1)CCC2

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.31
▸ CTSB P07858 1/20 0.31
▸ CTSK P43235 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20853810 1.00 CTSL (0.31) CTSLCTSBCTSK
SCHEMBL514300 0.94 ALDH1A1 (0.32) —
SCHEMBL514087 0.94 ALDH1A1 (0.32) —
SCHEMBL20853812 0.94 — —
SCHEMBL514418 0.94 — —
SCHEMBL513991 0.94 — —
SCHEMBL14433301 0.89 MGLL (0.38) —
SCHEMBL514846 0.88 MGLL (0.33) CTSLCTSBCTSK
SCHEMBL19593693 0.82 MGLL (0.40) —
SCHEMBL9501105 0.82 MGLL (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10859916-B2 Composition for forming fine pattern and method for forming fine pattern using the same MERCK PATENT GMBH (DE) 2020-12-08 — — US claimed
EP-4720172-A1 SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL Forschungszentrum Jülich GmbH (DE) 2026-04-08 — — EP disclosed
WO-2025242796-A1 HYDROGENATED SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENE-ANION EXCHANGE POLYMERS AS MEMBRANE MATERIALS FOR ALKALINE WATER ELECTROLYSIS AND FUEL CELLS Forschungszentrum Jülich GmbH (DE) 2025-11-27 — — WO disclosed
WO-2024245731-A1 SIDE-CHAIN FUNCTIONALIZED POLYNORBORNENES AS IONOMERS AND AS MEMBRANE MATERIALS FOR ALKALINE ELECTROLYSIS OF WATER, AND FUEL CELL Forschungszentrum Jülich GmbH (DE) 2024-12-05 — — WO disclosed
US-20240036469-A1 METHOD FOR MANUFACTURING THICKENED RESIST PATTERN, THICKENING SOLUTION, AND METHOD FOR MANUFACTURING PROCESSED SUBSTRATE MERCK ELECTRONICS LTD. (JP) 2024-02-01 — — US disclosed
EP-4264376-A1 METHOD FOR MANUFACTURING THICKENED RESIST PATTERN, THICKENING SOLUTION, AND METHOD FOR MANUFACTURING PROCESSED SUBSTRATE Merck Patent GmbH (DE) 2023-10-25 — — EP disclosed
WO-2022129015-A1 METHOD FOR MANUFACTURING THICKENED RESIST PATTERN, THICKENING SOLUTION, AND METHOD FOR MANUFACTURING PROCESSED SUBSTRATE MERCK PATENT GMBH (DE) 2022-06-23 — — WO disclosed
CN-108780284-B Composition for forming fine pattern and method for forming fine pattern using same AZ电子材料(卢森堡)有限公司 2022-04-12 — — CN disclosed
US-10859916-B2 Composition for forming fine pattern and method for forming fine pattern using the same MERCK PATENT GMBH (DE) 2020-12-08 — — US disclosed
EP-3430476-B1 COMPOSITION FOR FORMING FINE PATTERN AND METHOD FOR FORMING FINE PATTERN USING THE SAME AZ ELECTRONIC MAT LUXEMBOURG SARL (LU) 2020-04-01 — — EP disclosed
US-7112337-B2 Liposome composition for delivery of nucleic acid ALZA CORPORATION (US) 2006-09-26 — — US disclosed
WO-2006089168-A2 METHODS FOR MODULATING ION CHANNELS CORNELL RESEARCH FOUNDATION, INC. (US) 2006-08-24 — — WO disclosed
US-20050191344-A1 Liposome composition for delivery of therapeutic agents ALZA CORPORATION 2005-09-01 — — US disclosed
WO-2005070466-A2 LIPOSOME COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS ALZA CORPORATION (US) 2005-08-04 — — WO disclosed
WO-2005063745-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 — — WO disclosed
US-20040197390-A1 Neutral-cationic lipid for systemic delivery of factor VIII gene HUANG SHI-KUN (US) 2004-10-07 — — US disclosed
US-20040166150-A1 Neutral-cationic lipid for systemic delivery of Factor VIII gene HUANG SHI-KUN (US) 2004-08-26 — — US disclosed
US-20030031704-A1 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic ALZA CORPORATION 2003-02-13 — — US disclosed
US-4267383-A USING A COMPLEX CATALYST FROM A TRIARYL PHOSPHINE AND A RHODIUM CARBONYL HYDRIDE OR CHLORIDE CELANESE CORPORATION (US) 1981-05-12 — — US disclosed
US-4110404-A Hydrocarbonylation CELANESE CORPORATION (US) 1978-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197390-A1 Neutral-cationic lipid for systemic delivery of factor VIII gene F13B, F13A1, F8 CTSL 1521/4885CTSB 1212/4885CTSK 1292/4885
US-20050191344-A1 Liposome composition for delivery of therapeutic agents PHOSPHO1, LIPA, SGMS1 CTSL 1685/4885CTSB 1612/4885CTSK 2808/4885
US-20030031704-A1 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic DLST, LIPA, DNAJC10 CTSL 2225/4885CTSB 2405/4885CTSK 3739/4885
US-20040166150-A1 Neutral-cationic lipid for systemic delivery of Factor VIII gene F8, F13B, F13A1 CTSL 2805/4885CTSB 2456/4885CTSK 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback